Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

4D Molecular Therapeutics (FDMT) Research & Development (2020 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Research & Development for 6 consecutive years, with $49.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Research & Development rose 28.47% to $49.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $181.2 million, a 45.83% increase, with the full-year FY2024 number at $141.3 million, up 45.53% from a year prior.
  • Research & Development was $49.4 million for Q3 2025 at 4D Molecular Therapeutics, up from $48.0 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $49.4 million in Q3 2025 to a low of $12.8 million in Q1 2021.
  • A 5-year average of $27.3 million and a median of $23.6 million in 2023 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: decreased 3.16% in 2021, then skyrocketed 65.54% in 2024.
  • 4D Molecular Therapeutics' Research & Development stood at $17.5 million in 2021, then increased by 22.72% to $21.5 million in 2022, then increased by 21.0% to $26.0 million in 2023, then surged by 65.54% to $43.1 million in 2024, then increased by 14.74% to $49.4 million in 2025.
  • Per Business Quant, the three most recent readings for FDMT's Research & Development are $49.4 million (Q3 2025), $48.0 million (Q2 2025), and $40.7 million (Q1 2025).